Skip to main content

Miquel Vila Bover

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

Institutions of which they are part

Head of group
Neurodegenerative Diseases
Vall Hebron Institut de Recerca
Miquel Vila Bover

Miquel Vila Bover

Miquel Vila Bover

Institutions of which they are part

Head of group
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)

I have a degree in Medicine and Surgery from the University of Barcelona (1993) and a PhD in Neuroscience from the University of Paris 6 (1998). My doctoral work carried out in the laboratory of experimental neurology at the Salpetriere Hospital in Paris (1993-98) contributed to establishing the subthalamic nucleus as the main therapeutic target for the surgical treatment of Parkinson's disease with deep brain stimulation. From 1998 to 2005 I worked at the Movement Disorders Unit of Columbia University in New York (USA), initially as a postdoctoral researcher and from 2001 as an Assistant Professor of Neurology, focusing on the study of the mechanisms of neuronal death in Parkinson's disease to identify new therapeutic targets for this currently incurable neurodegenerative disorder.

In 2006 I moved to Barcelona as a Professor at ICREA (Catalan Institute of Research and Advanced Studies) to create and lead a new research group in neurodegenerative diseases at the Vall d'Hebron Research Institute (VHIR). Our group is now part of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) and the Aligning Science Across Parkinson's Collaborative Research Network (ASAP-CRN).

I am also an Associate Professor at the Autonomous University of Barcelona, Principal Investigator at CIBERNED, Coordinating Lead PI at ASAP-CRN and member of the Steering Committees of the World Parkinson Coalition and the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society.

Research lines

Role of mitochondria in Parkinson's disease

Mitochondria are highly dynamic organelles with complex structural features that play several important cellular functions, such as the production of energy by oxidative phosphorylation, the regulation of calcium homeostasis, or the control of programmed cell death. Given its essential role in neuronal viability, alterations in mitochondrial biology can lead to neuron dysfunction and cell death. Defects in mitochondrial respiration have long been implicated in the etiology and pathogenesis of Parkinson's disease (PD). However, the role of mitochondria in PD extends well beyond defective respiration and also involves perturbations in mitochondrial dynamics, leading to alterations in mitochondrial morphology, intracellular trafficking, or quality control. Whether a primary or secondary event, mitochondrial dysfunction holds promise as a potential therapeutic target to halt the progression of dopaminergic neurodegeneration in PD.

IP: Vila Bover, Miquel

Alpha-synuclein involvement in Parkinson's disease

Formation and accumulation of abnormal protein aggregates are a central hallmark of several neurodegenerative diseases. In Parkinson’s disease (PD), the aggregation-prone protein á-synuclein accumulates in several areas of the central and peripheral nervous system. Pathological á-synuclein accumulation in PD can result from (i) abnormally increased á-synuclein expression, (ii) defective intracellular clearance of á-synuclein protein, (iii) progressive self-propagation and spreading of pathological á-synuclein between interconnected brain areas. Targeting á-synuclein pathological changes may provide therapeutic benefit to delay, halt or prevent neuronal dysfunction and degeneration in PD.

IP: Vila Bover, Miquel

Neuromelanin and Parkinson's disease

In Parkinson's disease (PD), there is a selective degeneration of neurons that contain a dark-brown pigment called neuromelanin, especially dopaminergic neurons of the substantia nigra, which leads to the classical motor symptoms of the disease. However, the physiological significance of neuromelanin and its potential contribution to PD pathogenesis remain unknown.

IP: Vila Bover, Miquel

Identification of biomarkers of prodromal Parkinson's disease

Despite intensive efforts towards understanding the aetiology/pathogenesis of Parkinson's disease (PD) and the development of novel therapeutic approaches for this neurodegenerative condition, the current treatment for PD remains symptomatic and yet far from modifying disease onset or progression. Before the manifestation of the classical motor symptoms, PD patients present with non-motor symptoms in a prodromal phase. The identification of deregulated molecular pathways or genes in peripheral blood and/or cerebrospinal fluid from these prodromal patients may help develop potential biomarkers for the early detection, diagnosis, risk assessment and/or progression of PD, which are currently lacking, as well as to stratify patients at very early stages to apply more specific, personalized disease-modifying treatments.

IP: Vila Bover, Miquel, Laguna Tuset, Ariadna

Projects

Malalties neurodegeneratives

IP: Vila Bover, Miquel
Collaborators: Hernández Vara, Jorge, Compte Barrón, Joan, Martínez Vicente, Marta, Bove Badell, Jordi, Malalties neurodegeneratives , Camprodon Gomez, Maria, Malalties neurodegeneratives , Guillard Sirieix, Camille, Lorente Picón, Marina, Laura Castillo Ribelles, de Fabregues-Boixar Nebot, Oriol, Hoyo Pérez, Javier, Laguna Tuset, Ariadna, Cuadros Arasa, Thais, Riera Heredia, Jordi, Ramos Vicente, David, Malalties neurodegeneratives , Malalties neurodegeneratives , Xicoy Cortada, Helena, Nicolau Vera, Alba, González Sepúlveda, Marta, Malalties neurodegeneratives , Cladera Sastre, Joana Margalida, Parent , Annabelle, Daniela Samaniego Toro, Malalties neurodegeneratives
Funding agency: AGAUR no fer servir-correcte 4301-37
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 31/12/2024

MECANISMOS MOLECULARES DE NEURODEGENERACION LIGADA A LA NEUROMELANINA EN LA ENFERMEDAD DE PARKINSON Y ENVEJECIMIENTO CEREBRAL

IP: Vila Bover, Miquel
Collaborators: Roch Alba, Gerard, Izquierdo Sans , Miriam
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 99260
Reference: PRE2021-098300
Duration: 01/07/2022 - 30/06/2026

Ministerio de Ciencia

Activity and connectivity drive neuronal vulnerability and disease progression in Parkinson's disease

IP: Vila Bover, Miquel
Collaborators: Compte Barrón, Joan, Hoyo Pérez, Javier, Roch Alba, Gerard, González Sepúlveda, Marta, Laguna Tuset, Ariadna, Cladera Sastre, Joana Margalida
Funding agency: Michael J. Fox Foundation
Funding: 1269495.05
Reference: ASAP_MJFF2021
Duration: 01/11/2021 - 31/10/2024

Characterization of the CD8 T cell response in Parkinson’s disease for the development of preventive and therapeutic strategies that halt the progression of the disease: SARS-Cov-2-induced long term-hyposmia as a possible prodromal stage

IP: Bove Badell, Jordi
Collaborators: Vila Bover, Miquel, Ferré Masó, Alejandro, de Fabregues-Boixar Nebot, Oriol, Lorenzo Bosquet, Carles, Cuadros Arasa, Thais, Palasi Franco, Antonio, Ramos Vicente, David, Marchena Herrera, Mariona
Funding agency: Instituto de Salud Carlos III
Funding: 165770
Reference: PI21/01358
Duration: 01/01/2022 - 31/12/2024

Related news

Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, is the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, is a scientific ambassador.

Researchers describe the molecular mechanisms by which the GBA gene, the main genetic risk factor, associates with the accumulation of α-synuclein in neurons.

It is the project “New Nanotechnological Therapy for Parkinson’s disease: Nose to Brain Delivery of GBA-Polymer Nanoconjugates (nanoGBAtoBrain)”.

Related professionals

Anna  Abuli  Vidal

Anna Abuli Vidal

Postdoctoral researcher
Genetics Medicine
Read more
Jorge Aguilera Sáez

Jorge Aguilera Sáez

Read more
Isabel Claveria Guiu

Isabel Claveria Guiu

Infectious Diseases
Read more
Felipe Hernando Bartolome

Felipe Hernando Bartolome

Molecular Medical Imaging
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.